Abgentis is a startup based in the United Kingdom, 1 tracked investor.
Abgentis is a company headquartered in the United Kingdom. Brouky records 1 investor associated with the company.
Abgentis develops a new broad-spectrum intravenous and oral antibacterial treatment targeting acute, chronic, life-threatening, and drug-resistant infections by optimizing DNA supercoiling inhibitors for enhanced efficacy and low resistance.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.